Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Center for International Blood and Marrow Transplant Research
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06859424CT.gov A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | — | Recruiting | — | — | — |
NCT06001385CT.gov HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | — | Active Not Recruiting | — | — | — |
NCT00005803CT.gov Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prolymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Melphalan (this asset) | Center for International Blood and Marrow Transplant Research | P2 | BB · 65 |
| Cyclophosphamide | Center for International Blood and Marrow Transplant Research | P2 | BBB |
| Fludarabine | Center for International Blood and Marrow Transplant Research | P3 | BB |
| Nivestim | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
| Tacrolimus | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Busulfanum | Center for International Blood and Marrow Transplant Research | P2 | BB |
| Ibrutinib | Fred Hutchinson Cancer Center | P2 | B |
| Rituximab | Acerta Pharma BV | P2 | B |
+42 more in the Prolymphocytic Leukemia cohort
Other indications for Melphalan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 76 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 76 |
| Cancer Of Unknown Primary Site | — | P2/3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CyclophosphamideCenter for International Blood and Marrow Transplant ResearchBBB
- FludarabineCenter for International Blood and Marrow Transplant ResearchBB
- NivestimCenter for International Blood and Marrow Transplant ResearchBB
- Cyclosporin AFred Hutchinson Cancer CenterBB
- TacrolimusCenter for International Blood and Marrow Transplant ResearchBB
Citation
Floatz Terminal. Melphalan in Prolymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/melphalan-prolymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →